Teva Pharmaceutical Industries

NYSE
TEVA
Stock
Yield per half year: +3.81%
Dividend yield: 0%
Sector: Healthcare

Company Analysis Teva Pharmaceutical Industries

Download the report: word Word pdf PDF

1. Summary

Advantages

  • Price (17.71 $) is less than fair price (19.76 $)
  • The stock's return over the last year (-4.78%) is higher than the sector average (-17.94%).
  • Current debt level 45.97% is below 100% and has decreased over 5 years from 47.57%.
  • The company's current efficiency (ROE=-25.44%) is higher than the sector average (ROE=-83.32%)

Disadvantages

  • Dividends (0%) are below the sector average (1.28%).

Similar companies

Amicus Therapeutics, Inc.

Evolent Health

Varian Medical

Viela Bio, Inc.

2. Share price and performance

2.1. Share price

2.3. Market efficiency

Teva Pharmaceutical Industries Healthcare Index
7 days -0.3% -14.1% -0.6%
90 days 25.1% -18% 5.7%
1 year -4.8% -17.9% 9%

TEVA vs Sector: Teva Pharmaceutical Industries has outperformed the "Healthcare" sector by 13.15% over the past year.

TEVA vs Market: Teva Pharmaceutical Industries has significantly underperformed the market by -13.76% over the past year.

Stable price: TEVA is not significantly more volatile than the rest of the market on "New York Stock Exchange" over the last 3 months, with typical variations of +/- 5% per week.

Long period: TEVA with weekly volatility of -0.092% over the past year.

3. Summary of the report

3.1. General

P/E: 872
P/S: 1.53

3.2. Revenue

EPS -1.45
ROE -25.44%
ROA -3.96%
ROIC -0.29%
Ebitda margin 4.33%

4. Fundamental Analysis

4.1. Stock price and price forecast

The fair price is calculated taking into account the Central Bank refinancing rate and earnings per share (EPS)

Below fair price: The current price (17.71 $) is lower than the fair price (19.76 $).

Price not significantly lower than the fair price: The current price (17.71 $) is slightly lower than the fair price by 11.6%.

4.2. P/E

P/E vs Sector: The company's P/E (872) is higher than that of the sector as a whole (52.65).

P/E vs Market: The company's P/E (872) is higher than that of the market as a whole (61.83).

4.2.1 P/E Similar companies

4.3. P/BV

P/BV vs Sector: The company's P/BV (4.41) is lower than that of the sector as a whole (10.86).

P/BV vs Market: The company's P/BV (4.41) is lower than that of the market as a whole (20.82).

4.3.1 P/BV Similar companies

4.4. P/S

P/S vs Sector: The company's P/S indicator (1.53) is lower than that of the sector as a whole (4.03).

P/S vs Market: The company's P/S indicator (1.53) is lower than that of the market as a whole (16).

4.4.1 P/S Similar companies

4.5. EV/Ebitda

EV/Ebitda vs Sector: The company's EV/Ebitda (55.9) is higher than that of the sector as a whole (16.78).

EV/Ebitda vs Market: The company's EV/Ebitda (55.9) is higher than that of the market as a whole (27.04).

5. Profitability

5.1. Profitability and revenue

5.2. Earnings per share - EPS

5.3. Past profitability Net Income

Yield Trend: Negative and has fallen by -12.27% over the last 5 years.

Accelerating profitability: The return for the last year (0%) exceeds the average return for 5 years (-12.27%).

Profitability vs Sector: The return for the last year (0%) exceeds the return for the sector (-8.87%).

5.4. ROE

ROE vs Sector: The company's ROE (-25.44%) is higher than that of the sector as a whole (-83.32%).

ROE vs Market: The company's ROE (-25.44%) is lower than that of the market as a whole (43%).

5.5. ROA

ROA vs Sector: The company's ROA (-3.96%) is lower than that of the sector as a whole (6.43%).

ROA vs Market: The company's ROA (-3.96%) is lower than that of the market as a whole (23.28%).

5.6. ROIC

ROIC vs Sector: The company's ROIC (-0.29%) is lower than that of the sector as a whole (15.68%).

ROIC vs Market: The company's ROIC (-0.29%) is lower than that of the market as a whole (9.2%).

6. Finance

6.1. Assets and debt

Debt level: (45.97%) is quite low in relation to assets.

Debt reduction: over 5 years, the debt has decreased from 47.57% to 45.97%.

Excess of debt: The debt is not covered by net income, percentage -1103.05%.

6.2. Profit growth and share price

7. Dividends

7.1. Dividend yield vs Market

Low yield: The dividend yield of the company 0% is below the average for the sector '1.28%.

7.2. Stability and increase in payments

Unstable dividends: The company's dividend yield 0% has not been consistently paid over the past 7 years, DSI=0.43.

Weak dividend growth: The company's dividend yield 0% has been growing weakly or stagnant over the past 5 years. Growth over only 0 years.

7.3. Payout percentage

Dividend Coverage: Current payments from income (0%) are at an uncomfortable level.

8. Insider trades

8.1. Insider trading

Insider Buying Exceeds insider sales by 100% over the last 3 months.

8.2. Latest transactions

Pay for your subscription

More functionality and data for company and portfolio analysis is available by subscription

9. Stocks forum Teva Pharmaceutical Industries

9.3. Comments